Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director

Regulatory News:

Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director.

Jean-Louis Dasseux, founder and CEO of Cerenis, said: "We are proud to welcome Barbara Yanni to Cerenis' Board of Directors. This is a unique opportunity for us, as Barbara is highly regarded in the pharmaceutical industry as a business and financial expert with deep experience as a senior business development executive. Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Merck’s Vice President and Chief Licensing Officer. While at Merck, Barbara and her team successfully structured and negotiated agreements to acquire rights to over 150 compounds, programs and technologies to enhance Merck's pipeline.

Her endeavors also allowed Merck to be recognized as the "best biopharma partner". Without any doubt we will greatly benefit from her superb interpersonal skills and background to help Cerenis in future strategy and deal negotiations as we better understand large and small potential partners."

Barbara Yanni, JD, MA, BA - Independent Administrator

Former Vice President and Chief Licensing Officer at Merck & Co., Inc.

Barbara is currently an Independent Director of three other clinical-stage biotech companies: Trevena Inc. (NASDAQ: TRVN), Vaccinex, Inc. and Symic Bio. She has more than thirty years of experience in pharma and biotechnology. As Chief Licensing Officer at Merck & Co., Inc. she has built strong relationships within the pharmaceutical, biotech and venture community. She oversaw successful strategic collaborations for 33 clinical and/or commercial compounds, 13 preclinical compounds and more than 100 compounds at the discovery, formulation or research technology stage. Prior to her leadership roles in business development at Merck, Barbara conducted financial analyses of business development opportunities and employee benefits and devised and implemented strategies to minimize Merck’s corporate taxes.

Barbara Yanni holds an AB in Physics from Wellesley College, an LLM in Taxation from New York University and a JD from Stanford Law School.

About CERENIS: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular, metabolic diseases, and HDL platform technologies. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids are removed from arteries and transported to the liver for elimination from the body. In addition to advancing HDL technologies for drug delivery, CERENIS is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). Leveraging its expertise, Cerenis is developing the first platform for the targeted drug delivery by HDL dedicated to the field of oncology (immuno-oncology and chemotherapy).

CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.

About Targeted HDL Drug Delivery

HDL particles, loaded with an active agent, hold the promise to target and selectively kill malignant cells while sparing healthy ones. A wide variety of drugs can be embedded in these particles targeting markers specific to cancer cells and bring these potent drugs to their intended site of action, with lowered systemic toxicity. Cerenis intends to develop the first HDL-based targeting drug delivery platform dedicated to the oncology market, including immuno-oncology and chemotherapy.

Financial Calendar

2018 Half year Results: September 11^th, 2018

View source version on businesswire.com: https://www.businesswire.com/news/home/20180731005747/en/